ARCHIVES

In brief: Cancer Investment “Drop In The Bucket,” OMB Is The “Second Greatest Kill,” Pepper Says

This article is from The Cancer Letter archive.

Vol. 05 No. 32 | August 10, 1979

Download PDF Visit The Full Archive

Related Articles

EntreMed Begins Phase I/II Trial For Endostatin.

July 27, 2001

Early ADT Doesn’t Offer Survival Advantage—ASCO

April 27, 2007

Scripps, Sandoz Deal Becomes Case Study As NI Rethinks Sponsored Research

January 28, 1994

In Brief: NCI’s John Czajkowski Takes Executive Dean Position At Harvard Medical School

February 21, 2014

Also in this 8-page Issue: Safety Warnings Are Added to Labels for Epo and Avastin.

January 21, 2005

In Brief: Three Comprehensive Centers Have Problems But Aren’t On “Probation”; Amos On Budget

June 9, 1978